2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Biological Processes, Pathogenesis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4425 Demographic variables influence CML Patients’ valuation of TKI therapy

Audrey Propp, BA, Nidhi Sharma, MS, Ph.D2, Qiuhong Zhao, MS3, Jennifer E Vaughn, MD, MSPH4
1 Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, United States
2 Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, United States
3 Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, United States
4 Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, United States

Introduction: Tyrosine kinase inhibitors (TKIs) dramatically improved survival among patients with chronic myeloid leukemia (CML). Despite this, concerns remain regarding the financial impact to patients who cover significant co-pays. In recent years, 2nd generation TKIs are moving to generic form, along with imatinib. Simultaneously, newer, more expensive CML treatments are now approved or are under development. Thus, it becomes increasingly important to understand how patients with CML prioritize drug cost in shared, treatment decision-making.

Hypothetical purchasing task questionnaires (HPTs) study motivation for consumption of products under rising cost constraints and provide insight into consumer demand. To date, this method has not been applied to assess patient demand for expensive cancer drugs.

Purpose: This study trialed a novel, CML specific HPT to test the hypothesis that certain socioeconomic factors (marital status, income, education level, race) influence TKI valuation among patients with the disease.

Methods: Patients treated at Ohio State for a diagnosis of CML in chronic phase who had been prescribed TKI therapy for at least 1 year were recruited. All participants completed a demographic survey.  The first 50 participants enrolled completed the first version of a novel CML HPT, ranking the likelihood of taking their TKI as prescribed on a scale of 0%-100%. This task was repeated 11 times, each with an increasing increment of out-of-pocket monthly cost (range $0-$2000). In this HPT version, patients were asked to assume their current TKI was the only available therapy. A second version of this task was introduced to the next 47 participants enrolled. This task assessed whether the same factors predicted TKI valuation when 1) the price range was increased to up to $10,000 per month and 2) another medication was available with 50% less efficacy and no out-of-pocket costs.

“Valuation” breakpoints were defined as the monthly, out-of-pocket cost at which patients reported themselves 0% likely (breakpoint0) and for the first time 50% less likely (breakpoint50) to take their TKI as prescribed. Wilcoxon rank sum test or Fisher's exact test was used to evaluate the associations between variables of interest depending on data types.

Results: Ninety-seven patients (age 19-80, 54% male) participated. 82% of patients were taking 2nd or higher generation TKIs. Sixty nine % were married, 13% non-Caucasian, 66% had < 4-year college degree, 30% earned < $50,000 annually.

In the first HPT (N=97), median breakpoint0 and breakpoint50 costs were $1000 and $200, respectively. Lower annual income (<$50,000), non-Caucasian race, non-married status, and < 4-year college were associated with lower median breakpoint0 ($200 vs. $1000, p= 0.012, $100 vs. $1000, p=0.018, $200 vs. $1000, p=0.001, and $500 vs. $2000, p=0.024 respectively).   Income, race, < 4-years of college, and non-married status were associated with lower breakpoint50 (p=0.028, 0.035, 0.008, and 0.014, respectively).

When a free, 50% less effective alternate treatment was available (N=47), median breakpoint0 and breakpoint50 costs were $1000 and $500. Non-married status was associated with lower breakpoint0 ($200 vs. $1000, p=0.012).  While not statistically significant, breakpoint0 among participants with < 4 years education was $750 compared to $5000 (p=0.088). Non-married status and <4-years of college were associated with lower breakpoint50 (p=0.034 and p=0.029, respectively).  

Conclusions: As the TKI market diversifies, HPTs may provide a unique tool to study patient demand for these life-saving drugs. Adapting HPTs to study cancer populations requires continued refinement. In our cohort of CML patients, demographic features such as race, income, education and marital status appeared to have some influence on patient valuation of TKI therapy. The impact of marital status and education are particularly interesting and deserve further investigation.

While limited by a small N, this study demonstrates that in current US healthcare system, even life-saving therapies have a price at which they lose their inherent value to the “patient-consumer”.   Future studies will adapt the CML HPT to study patient preferences in more realistic cost scenarios and to detect preference between more effective vs. well-tolerated therapies.

Jennifer E Vaughn, MD, MSPH: Takeda - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony)